Physician profile
Jun Lin
NPI 1053065847
$993.40
in general payments reported to CMS, 2019-2025
8 companies · $31.17 in 2025
The $31.17 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $535 · 2024: $427 · 2025: $31.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $993.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $260.79 | 2023-2024 | |
| Madrigal Pharmaceuticals | $144.08 | 2024 | Rezdiffra |
| Abbvie INC. | $124.94 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.06 | 2023 | Xifaxan |
| Ardelyx, INC. | $121.32 | 2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $106.58 | 2024 | Iqirvo |
| Glaxosmithkline, LLC. | $82.46 | 2024 | |
| Solventum Corporation | $31.17 | 2025 | Activ.A.C. |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.